nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHB4—breast cancer	0.0903	0.195	CbGaD
Crizotinib—ACVR1—breast cancer	0.0767	0.166	CbGaD
Crizotinib—AURKA—Epirubicin—breast cancer	0.0701	0.352	CbGbCtD
Crizotinib—AURKA—breast cancer	0.0495	0.107	CbGaD
Crizotinib—MET—breast cancer	0.0484	0.105	CbGaD
Crizotinib—IGF1R—breast cancer	0.0456	0.0988	CbGaD
Crizotinib—ALK—breast cancer	0.0414	0.0897	CbGaD
Crizotinib—CSF1R—breast cancer	0.0393	0.0851	CbGaD
Crizotinib—AURKA—Doxorubicin—breast cancer	0.0372	0.187	CbGbCtD
Crizotinib—ABL1—breast cancer	0.0306	0.0662	CbGaD
Crizotinib—SRC—breast cancer	0.0277	0.0599	CbGaD
Crizotinib—CYP3A5—Lapatinib—breast cancer	0.0074	0.0372	CbGbCtD
Crizotinib—CYP3A4—breast cancer	0.00679	0.0147	CbGaD
Crizotinib—ABCB1—Toremifene—breast cancer	0.0066	0.0332	CbGbCtD
Crizotinib—CYP3A4—Exemestane—breast cancer	0.00571	0.0287	CbGbCtD
Crizotinib—ABCB1—breast cancer	0.00565	0.0122	CbGaD
Crizotinib—CYP3A4—Letrozole—breast cancer	0.00485	0.0244	CbGbCtD
Crizotinib—ABCB1—Lapatinib—breast cancer	0.00482	0.0242	CbGbCtD
Crizotinib—CYP3A4—Anastrozole—breast cancer	0.00432	0.0218	CbGbCtD
Crizotinib—CYP3A4—Toremifene—breast cancer	0.00396	0.0199	CbGbCtD
Crizotinib—CYP3A5—Tamoxifen—breast cancer	0.00371	0.0186	CbGbCtD
Crizotinib—CYP3A4—Fulvestrant—breast cancer	0.00368	0.0185	CbGbCtD
Crizotinib—CYP3A4—Thiotepa—breast cancer	0.00328	0.0165	CbGbCtD
Crizotinib—CYP3A4—Ixabepilone—breast cancer	0.003	0.0151	CbGbCtD
Crizotinib—CYP3A4—Lapatinib—breast cancer	0.00289	0.0145	CbGbCtD
Crizotinib—CYP3A5—Paclitaxel—breast cancer	0.00288	0.0145	CbGbCtD
Crizotinib—CYP3A5—Irinotecan—breast cancer	0.00285	0.0143	CbGbCtD
Crizotinib—ABCB1—Vinorelbine—breast cancer	0.00267	0.0134	CbGbCtD
Crizotinib—ABCB1—Tamoxifen—breast cancer	0.00241	0.0121	CbGbCtD
Crizotinib—ABCB1—Mitoxantrone—breast cancer	0.00235	0.0118	CbGbCtD
Crizotinib—CYP3A4—Raloxifene—breast cancer	0.00219	0.011	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—breast cancer	0.00208	0.0105	CbGbCtD
Crizotinib—ABCB1—Gemcitabine—breast cancer	0.00208	0.0104	CbGbCtD
Crizotinib—ABCB1—Paclitaxel—breast cancer	0.00188	0.00944	CbGbCtD
Crizotinib—ABCB1—Irinotecan—breast cancer	0.00185	0.00931	CbGbCtD
Crizotinib—ABCB1—Vinblastine—breast cancer	0.00165	0.00828	CbGbCtD
Crizotinib—CYP3A4—Vinorelbine—breast cancer	0.0016	0.00805	CbGbCtD
Crizotinib—CYP3A4—Tamoxifen—breast cancer	0.00144	0.00727	CbGbCtD
Crizotinib—CYP3A4—Mitoxantrone—breast cancer	0.00141	0.00709	CbGbCtD
Crizotinib—ABCB1—Docetaxel—breast cancer	0.00136	0.00682	CbGbCtD
Crizotinib—CYP3A4—Paclitaxel—breast cancer	0.00112	0.00566	CbGbCtD
Crizotinib—CYP3A4—Irinotecan—breast cancer	0.00111	0.00558	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—breast cancer	0.00101	0.00509	CbGbCtD
Crizotinib—CYP3A4—Vinblastine—breast cancer	0.000986	0.00496	CbGbCtD
Crizotinib—ABCB1—Methotrexate—breast cancer	0.00098	0.00493	CbGbCtD
Crizotinib—CYP3A4—Docetaxel—breast cancer	0.000813	0.00409	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—breast cancer	0.000606	0.00305	CbGbCtD
Crizotinib—TESK1—Estradiol—Fulvestrant—breast cancer	0.000239	0.0915	CbGdCrCtD
Crizotinib—IGF1R—Topotecan—Irinotecan—breast cancer	0.000214	0.0819	CbGdCrCtD
Crizotinib—CDK7—Topotecan—Irinotecan—breast cancer	0.000173	0.0661	CbGdCrCtD
Crizotinib—AURKA—Chlorambucil—Melphalan—breast cancer	0.000153	0.0584	CbGdCrCtD
Crizotinib—MAP4K5—endometrium—breast cancer	0.000117	0.0014	CbGeAlD
Crizotinib—MAP3K3—endometrium—breast cancer	0.000117	0.0014	CbGeAlD
Crizotinib—TEK—endometrium—breast cancer	0.000117	0.0014	CbGeAlD
Crizotinib—RIPK2—adrenal gland—breast cancer	0.000117	0.0014	CbGeAlD
Crizotinib—RPS6KB1—pituitary gland—breast cancer	0.000117	0.0014	CbGeAlD
Crizotinib—RPS6KB1—adipose tissue—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—FGR—pituitary gland—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—MERTK—endocrine gland—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—SRC—epithelium—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—EPHA4—female reproductive system—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—AXL—pituitary gland—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—LCK—adipose tissue—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—FGR—adipose tissue—breast cancer	0.000116	0.00139	CbGeAlD
Crizotinib—AXL—adipose tissue—breast cancer	0.000115	0.00138	CbGeAlD
Crizotinib—ABL2—female gonad—breast cancer	0.000115	0.00138	CbGeAlD
Crizotinib—PTK2B—bone marrow—breast cancer	0.000114	0.00137	CbGeAlD
Crizotinib—BMP2K—female gonad—breast cancer	0.000114	0.00136	CbGeAlD
Crizotinib—MAP3K2—female reproductive system—breast cancer	0.000113	0.00136	CbGeAlD
Crizotinib—LIMK2—endocrine gland—breast cancer	0.000113	0.00136	CbGeAlD
Crizotinib—SLK—uterus—breast cancer	0.000113	0.00136	CbGeAlD
Crizotinib—RIPK2—bone marrow—breast cancer	0.000113	0.00136	CbGeAlD
Crizotinib—EPHA4—adrenal gland—breast cancer	0.000113	0.00135	CbGeAlD
Crizotinib—PLK4—Topotecan—Irinotecan—breast cancer	0.000113	0.043	CbGdCrCtD
Crizotinib—EPHB4—uterus—breast cancer	0.000112	0.00135	CbGeAlD
Crizotinib—MAP3K12—endocrine gland—breast cancer	0.000112	0.00134	CbGeAlD
Crizotinib—FLT3—endocrine gland—breast cancer	0.000112	0.00134	CbGeAlD
Crizotinib—ACVR1—endocrine gland—breast cancer	0.000112	0.00134	CbGeAlD
Crizotinib—EPHB6—endometrium—breast cancer	0.000112	0.00134	CbGeAlD
Crizotinib—MET—lymph node—breast cancer	0.000111	0.00134	CbGeAlD
Crizotinib—SLK—pituitary gland—breast cancer	0.000111	0.00133	CbGeAlD
Crizotinib—PTK2—female reproductive system—breast cancer	0.000111	0.00133	CbGeAlD
Crizotinib—TBK1—female reproductive system—breast cancer	0.000111	0.00133	CbGeAlD
Crizotinib—SLK—adipose tissue—breast cancer	0.000111	0.00133	CbGeAlD
Crizotinib—MAP3K2—adrenal gland—breast cancer	0.000111	0.00133	CbGeAlD
Crizotinib—EPHB4—pituitary gland—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—TYK2—female reproductive system—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—SRC—skin of body—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—EPHB4—adipose tissue—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—STK35—endocrine gland—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—PTK2B—female gonad—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—JAK2—pituitary gland—breast cancer	0.00011	0.00132	CbGeAlD
Crizotinib—JAK2—adipose tissue—breast cancer	0.000109	0.00131	CbGeAlD
Crizotinib—IRAK1—female reproductive system—breast cancer	0.000109	0.00131	CbGeAlD
Crizotinib—RIPK2—female gonad—breast cancer	0.000109	0.00131	CbGeAlD
Crizotinib—PTK2—adrenal gland—breast cancer	0.000108	0.0013	CbGeAlD
Crizotinib—TBK1—adrenal gland—breast cancer	0.000108	0.0013	CbGeAlD
Crizotinib—EPHA2—pituitary gland—breast cancer	0.000108	0.0013	CbGeAlD
Crizotinib—EPHA2—adipose tissue—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—YES1—endometrium—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—CDK7—lymph node—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—TYK2—adrenal gland—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—TEK—uterus—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—MAP4K5—uterus—breast cancer	0.000108	0.00129	CbGeAlD
Crizotinib—MAP3K2—bone marrow—breast cancer	0.000107	0.00128	CbGeAlD
Crizotinib—TAOK2—lymph node—breast cancer	0.000107	0.00128	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—breast cancer	0.000107	0.00128	CbGeAlD
Crizotinib—TAOK3—endometrium—breast cancer	0.000107	0.00128	CbGeAlD
Crizotinib—IRAK1—adrenal gland—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—FGR—female reproductive system—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—AXL—female reproductive system—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—BMP2K—endocrine gland—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—TEK—pituitary gland—breast cancer	0.000106	0.00127	CbGeAlD
Crizotinib—TEK—adipose tissue—breast cancer	0.000105	0.00126	CbGeAlD
Crizotinib—MAP3K3—adipose tissue—breast cancer	0.000105	0.00126	CbGeAlD
Crizotinib—MAP4K5—adipose tissue—breast cancer	0.000105	0.00126	CbGeAlD
Crizotinib—EPHA4—female gonad—breast cancer	0.000105	0.00126	CbGeAlD
Crizotinib—TBK1—bone marrow—breast cancer	0.000105	0.00126	CbGeAlD
Crizotinib—RPS6KB1—adrenal gland—breast cancer	0.000104	0.00125	CbGeAlD
Crizotinib—TYK2—bone marrow—breast cancer	0.000104	0.00125	CbGeAlD
Crizotinib—FGR—adrenal gland—breast cancer	0.000104	0.00124	CbGeAlD
Crizotinib—LCK—adrenal gland—breast cancer	0.000104	0.00124	CbGeAlD
Crizotinib—AXL—adrenal gland—breast cancer	0.000103	0.00124	CbGeAlD
Crizotinib—MAP3K2—female gonad—breast cancer	0.000103	0.00124	CbGeAlD
Crizotinib—EPHA3—lymph node—breast cancer	0.000103	0.00124	CbGeAlD
Crizotinib—ACVR1B—lymph node—breast cancer	0.000103	0.00124	CbGeAlD
Crizotinib—IRAK1—bone marrow—breast cancer	0.000103	0.00123	CbGeAlD
Crizotinib—PTK2B—endocrine gland—breast cancer	0.000102	0.00122	CbGeAlD
Crizotinib—RIPK2—endocrine gland—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—EPHB4—female reproductive system—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—TBK1—female gonad—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—PTK2—female gonad—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—EPHB6—pituitary gland—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—ABL1—embryo—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—EPHB6—adipose tissue—breast cancer	0.000101	0.00121	CbGeAlD
Crizotinib—TYK2—female gonad—breast cancer	0.0001	0.0012	CbGeAlD
Crizotinib—JAK2—female reproductive system—breast cancer	0.0001	0.0012	CbGeAlD
Crizotinib—FGR—bone marrow—breast cancer	0.0001	0.0012	CbGeAlD
Crizotinib—LCK—bone marrow—breast cancer	0.0001	0.0012	CbGeAlD
Crizotinib—YES1—uterus—breast cancer	9.94e-05	0.00119	CbGeAlD
Crizotinib—SLK—adrenal gland—breast cancer	9.94e-05	0.00119	CbGeAlD
Crizotinib—EPHA2—female reproductive system—breast cancer	9.92e-05	0.00119	CbGeAlD
Crizotinib—IRAK1—female gonad—breast cancer	9.91e-05	0.00119	CbGeAlD
Crizotinib—CSF1R—skin of body—breast cancer	9.88e-05	0.00119	CbGeAlD
Crizotinib—EPHB4—adrenal gland—breast cancer	9.87e-05	0.00118	CbGeAlD
Crizotinib—STK10—uterus—breast cancer	9.85e-05	0.00118	CbGeAlD
Crizotinib—JAK3—lymph node—breast cancer	9.82e-05	0.00118	CbGeAlD
Crizotinib—TAOK3—uterus—breast cancer	9.81e-05	0.00118	CbGeAlD
Crizotinib—JAK2—adrenal gland—breast cancer	9.8e-05	0.00118	CbGeAlD
Crizotinib—EPHA4—endocrine gland—breast cancer	9.79e-05	0.00117	CbGeAlD
Crizotinib—DCLK1—lymph node—breast cancer	9.76e-05	0.00117	CbGeAlD
Crizotinib—YES1—pituitary gland—breast cancer	9.76e-05	0.00117	CbGeAlD
Crizotinib—RPS6KB1—female gonad—breast cancer	9.73e-05	0.00117	CbGeAlD
Crizotinib—YES1—adipose tissue—breast cancer	9.72e-05	0.00117	CbGeAlD
Crizotinib—PLK4—lymph node—breast cancer	9.7e-05	0.00116	CbGeAlD
Crizotinib—EPHA2—adrenal gland—breast cancer	9.68e-05	0.00116	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—breast cancer	9.68e-05	0.00116	CbGeAlD
Crizotinib—TEK—female reproductive system—breast cancer	9.68e-05	0.00116	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—breast cancer	9.68e-05	0.00116	CbGeAlD
Crizotinib—LCK—female gonad—breast cancer	9.67e-05	0.00116	CbGeAlD
Crizotinib—FGR—female gonad—breast cancer	9.67e-05	0.00116	CbGeAlD
Crizotinib—STK4—lymph node—breast cancer	9.64e-05	0.00116	CbGeAlD
Crizotinib—TAOK3—pituitary gland—breast cancer	9.64e-05	0.00116	CbGeAlD
Crizotinib—STK10—adipose tissue—breast cancer	9.64e-05	0.00116	CbGeAlD
Crizotinib—AXL—female gonad—breast cancer	9.63e-05	0.00115	CbGeAlD
Crizotinib—SLK—bone marrow—breast cancer	9.62e-05	0.00115	CbGeAlD
Crizotinib—MAP3K2—endocrine gland—breast cancer	9.6e-05	0.00115	CbGeAlD
Crizotinib—TAOK3—adipose tissue—breast cancer	9.6e-05	0.00115	CbGeAlD
Crizotinib—EPHB4—bone marrow—breast cancer	9.55e-05	0.00115	CbGeAlD
Crizotinib—JAK2—bone marrow—breast cancer	9.48e-05	0.00114	CbGeAlD
Crizotinib—ABL1—Topotecan—Irinotecan—breast cancer	9.46e-05	0.0362	CbGdCrCtD
Crizotinib—TEK—adrenal gland—breast cancer	9.44e-05	0.00113	CbGeAlD
Crizotinib—MAP4K5—adrenal gland—breast cancer	9.44e-05	0.00113	CbGeAlD
Crizotinib—MAP3K3—adrenal gland—breast cancer	9.44e-05	0.00113	CbGeAlD
Crizotinib—PTK2—endocrine gland—breast cancer	9.4e-05	0.00113	CbGeAlD
Crizotinib—TBK1—endocrine gland—breast cancer	9.4e-05	0.00113	CbGeAlD
Crizotinib—SRC—adipose tissue—breast cancer	9.35e-05	0.00112	CbGeAlD
Crizotinib—TYK2—endocrine gland—breast cancer	9.34e-05	0.00112	CbGeAlD
Crizotinib—CSF1R—endometrium—breast cancer	9.32e-05	0.00112	CbGeAlD
Crizotinib—SLK—female gonad—breast cancer	9.27e-05	0.00111	CbGeAlD
Crizotinib—EPHB4—female gonad—breast cancer	9.2e-05	0.0011	CbGeAlD
Crizotinib—JAK2—female gonad—breast cancer	9.14e-05	0.0011	CbGeAlD
Crizotinib—MAP3K3—bone marrow—breast cancer	9.14e-05	0.0011	CbGeAlD
Crizotinib—MAP4K5—bone marrow—breast cancer	9.14e-05	0.0011	CbGeAlD
Crizotinib—FER—lymph node—breast cancer	9.11e-05	0.00109	CbGeAlD
Crizotinib—ALK—lymph node—breast cancer	9.11e-05	0.00109	CbGeAlD
Crizotinib—RPS6KB1—endocrine gland—breast cancer	9.04e-05	0.00108	CbGeAlD
Crizotinib—EPHA2—female gonad—breast cancer	9.03e-05	0.00108	CbGeAlD
Crizotinib—EPHB6—adrenal gland—breast cancer	9.03e-05	0.00108	CbGeAlD
Crizotinib—TNK1—lymph node—breast cancer	9.02e-05	0.00108	CbGeAlD
Crizotinib—FGR—endocrine gland—breast cancer	8.99e-05	0.00108	CbGeAlD
Crizotinib—AXL—endocrine gland—breast cancer	8.95e-05	0.00107	CbGeAlD
Crizotinib—YES1—female reproductive system—breast cancer	8.94e-05	0.00107	CbGeAlD
Crizotinib—BMPR1B—lymph node—breast cancer	8.93e-05	0.00107	CbGeAlD
Crizotinib—MAP4K1—lymph node—breast cancer	8.93e-05	0.00107	CbGeAlD
Crizotinib—STK10—female reproductive system—breast cancer	8.86e-05	0.00106	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Idarubicin—breast cancer	8.84e-05	0.0338	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Idarubicin—breast cancer	8.84e-05	0.0338	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Idarubicin—breast cancer	8.84e-05	0.0338	CbGdCrCtD
Crizotinib—TAOK3—female reproductive system—breast cancer	8.82e-05	0.00106	CbGeAlD
Crizotinib—AURKA—Topotecan—Irinotecan—breast cancer	8.81e-05	0.0337	CbGdCrCtD
Crizotinib—MAP4K5—female gonad—breast cancer	8.81e-05	0.00106	CbGeAlD
Crizotinib—MAP3K3—female gonad—breast cancer	8.81e-05	0.00106	CbGeAlD
Crizotinib—TEK—female gonad—breast cancer	8.81e-05	0.00106	CbGeAlD
Crizotinib—TNK2—lymph node—breast cancer	8.76e-05	0.00105	CbGeAlD
Crizotinib—IGF1R—lymph node—breast cancer	8.76e-05	0.00105	CbGeAlD
Crizotinib—YES1—adrenal gland—breast cancer	8.72e-05	0.00105	CbGeAlD
Crizotinib—STK10—adrenal gland—breast cancer	8.64e-05	0.00104	CbGeAlD
Crizotinib—MAP4K2—lymph node—breast cancer	8.63e-05	0.00104	CbGeAlD
Crizotinib—TAOK3—adrenal gland—breast cancer	8.61e-05	0.00103	CbGeAlD
Crizotinib—SRC—female reproductive system—breast cancer	8.6e-05	0.00103	CbGeAlD
Crizotinib—CSF1R—uterus—breast cancer	8.59e-05	0.00103	CbGeAlD
Crizotinib—EPHB4—endocrine gland—breast cancer	8.56e-05	0.00103	CbGeAlD
Crizotinib—TIE1—lymph node—breast cancer	8.52e-05	0.00102	CbGeAlD
Crizotinib—STK3—lymph node—breast cancer	8.52e-05	0.00102	CbGeAlD
Crizotinib—JAK2—endocrine gland—breast cancer	8.5e-05	0.00102	CbGeAlD
Crizotinib—YES1—bone marrow—breast cancer	8.44e-05	0.00101	CbGeAlD
Crizotinib—CSF1R—pituitary gland—breast cancer	8.43e-05	0.00101	CbGeAlD
Crizotinib—EPHB6—female gonad—breast cancer	8.42e-05	0.00101	CbGeAlD
Crizotinib—CSF1R—adipose tissue—breast cancer	8.4e-05	0.00101	CbGeAlD
Crizotinib—EPHA2—endocrine gland—breast cancer	8.39e-05	0.00101	CbGeAlD
Crizotinib—SRC—adrenal gland—breast cancer	8.39e-05	0.00101	CbGeAlD
Crizotinib—STK10—bone marrow—breast cancer	8.36e-05	0.001	CbGeAlD
Crizotinib—TAOK3—bone marrow—breast cancer	8.33e-05	0.000999	CbGeAlD
Crizotinib—AURKA—lymph node—breast cancer	8.3e-05	0.000996	CbGeAlD
Crizotinib—TESK1—lymph node—breast cancer	8.23e-05	0.000988	CbGeAlD
Crizotinib—MAP4K5—endocrine gland—breast cancer	8.19e-05	0.000982	CbGeAlD
Crizotinib—MAP3K3—endocrine gland—breast cancer	8.19e-05	0.000982	CbGeAlD
Crizotinib—TEK—endocrine gland—breast cancer	8.19e-05	0.000982	CbGeAlD
Crizotinib—YES1—female gonad—breast cancer	8.13e-05	0.000975	CbGeAlD
Crizotinib—STK10—female gonad—breast cancer	8.06e-05	0.000967	CbGeAlD
Crizotinib—TAOK3—female gonad—breast cancer	8.03e-05	0.000963	CbGeAlD
Crizotinib—MERTK—lymph node—breast cancer	8.01e-05	0.000961	CbGeAlD
Crizotinib—LIMK2—lymph node—breast cancer	7.83e-05	0.00094	CbGeAlD
Crizotinib—SRC—female gonad—breast cancer	7.82e-05	0.000938	CbGeAlD
Crizotinib—ABL1—skin of body—breast cancer	7.81e-05	0.000937	CbGeAlD
Crizotinib—NUAK2—lymph node—breast cancer	7.81e-05	0.000936	CbGeAlD
Crizotinib—MAP3K12—lymph node—breast cancer	7.75e-05	0.00093	CbGeAlD
Crizotinib—FLT3—lymph node—breast cancer	7.75e-05	0.00093	CbGeAlD
Crizotinib—ACVR1—lymph node—breast cancer	7.75e-05	0.00093	CbGeAlD
Crizotinib—CSF1R—female reproductive system—breast cancer	7.72e-05	0.000926	CbGeAlD
Crizotinib—STK35—lymph node—breast cancer	7.59e-05	0.000911	CbGeAlD
Crizotinib—YES1—endocrine gland—breast cancer	7.56e-05	0.000907	CbGeAlD
Crizotinib—CSF1R—adrenal gland—breast cancer	7.53e-05	0.000904	CbGeAlD
Crizotinib—STK10—endocrine gland—breast cancer	7.49e-05	0.000899	CbGeAlD
Crizotinib—TAOK3—endocrine gland—breast cancer	7.47e-05	0.000896	CbGeAlD
Crizotinib—ABL2—lymph node—breast cancer	7.4e-05	0.000888	CbGeAlD
Crizotinib—ABL1—endometrium—breast cancer	7.37e-05	0.000883	CbGeAlD
Crizotinib—BMP2K—lymph node—breast cancer	7.31e-05	0.000877	CbGeAlD
Crizotinib—CSF1R—bone marrow—breast cancer	7.29e-05	0.000874	CbGeAlD
Crizotinib—SRC—endocrine gland—breast cancer	7.28e-05	0.000873	CbGeAlD
Crizotinib—PTK2B—lymph node—breast cancer	7.06e-05	0.000847	CbGeAlD
Crizotinib—CSF1R—female gonad—breast cancer	7.02e-05	0.000842	CbGeAlD
Crizotinib—RIPK2—lymph node—breast cancer	7e-05	0.00084	CbGeAlD
Crizotinib—ABL1—uterus—breast cancer	6.79e-05	0.000814	CbGeAlD
Crizotinib—EPHA4—lymph node—breast cancer	6.77e-05	0.000812	CbGeAlD
Crizotinib—ABL1—pituitary gland—breast cancer	6.67e-05	0.000799	CbGeAlD
Crizotinib—ABL1—adipose tissue—breast cancer	6.64e-05	0.000796	CbGeAlD
Crizotinib—MAP3K2—lymph node—breast cancer	6.64e-05	0.000796	CbGeAlD
Crizotinib—CSF1R—endocrine gland—breast cancer	6.53e-05	0.000783	CbGeAlD
Crizotinib—PTK2—lymph node—breast cancer	6.5e-05	0.00078	CbGeAlD
Crizotinib—TBK1—lymph node—breast cancer	6.5e-05	0.00078	CbGeAlD
Crizotinib—TYK2—lymph node—breast cancer	6.46e-05	0.000774	CbGeAlD
Crizotinib—IRAK1—lymph node—breast cancer	6.37e-05	0.000764	CbGeAlD
Crizotinib—RPS6KB1—lymph node—breast cancer	6.25e-05	0.00075	CbGeAlD
Crizotinib—FGR—lymph node—breast cancer	6.21e-05	0.000745	CbGeAlD
Crizotinib—LCK—lymph node—breast cancer	6.21e-05	0.000745	CbGeAlD
Crizotinib—AXL—lymph node—breast cancer	6.19e-05	0.000742	CbGeAlD
Crizotinib—ABL1—female reproductive system—breast cancer	6.1e-05	0.000732	CbGeAlD
Crizotinib—SLK—lymph node—breast cancer	5.96e-05	0.000715	CbGeAlD
Crizotinib—ABL1—adrenal gland—breast cancer	5.95e-05	0.000714	CbGeAlD
Crizotinib—EPHB4—lymph node—breast cancer	5.92e-05	0.00071	CbGeAlD
Crizotinib—JAK2—lymph node—breast cancer	5.87e-05	0.000705	CbGeAlD
Crizotinib—EPHA2—lymph node—breast cancer	5.8e-05	0.000696	CbGeAlD
Crizotinib—PLK4—Doxorubicin—Idarubicin—breast cancer	5.76e-05	0.022	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Idarubicin—breast cancer	5.76e-05	0.022	CbGdCrCtD
Crizotinib—ABL1—bone marrow—breast cancer	5.76e-05	0.000691	CbGeAlD
Crizotinib—MAP3K3—lymph node—breast cancer	5.66e-05	0.000679	CbGeAlD
Crizotinib—MAP4K5—lymph node—breast cancer	5.66e-05	0.000679	CbGeAlD
Crizotinib—TEK—lymph node—breast cancer	5.66e-05	0.000679	CbGeAlD
Crizotinib—ABL1—female gonad—breast cancer	5.55e-05	0.000666	CbGeAlD
Crizotinib—EPHB6—lymph node—breast cancer	5.41e-05	0.000649	CbGeAlD
Crizotinib—ACVR1—Dexamethasone—Fluoxymesterone—breast cancer	5.3e-05	0.0203	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Fluoxymesterone—breast cancer	5.3e-05	0.0203	CbGdCrCtD
Crizotinib—YES1—lymph node—breast cancer	5.23e-05	0.000627	CbGeAlD
Crizotinib—STK10—lymph node—breast cancer	5.18e-05	0.000621	CbGeAlD
Crizotinib—ABL1—endocrine gland—breast cancer	5.16e-05	0.000619	CbGeAlD
Crizotinib—TAOK3—lymph node—breast cancer	5.16e-05	0.000619	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Epirubicin—breast cancer	5.04e-05	0.0193	CbGdCrCtD
Crizotinib—SRC—lymph node—breast cancer	5.03e-05	0.000603	CbGeAlD
Crizotinib—ABL1—Doxorubicin—Idarubicin—breast cancer	4.84e-05	0.0185	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Idarubicin—breast cancer	4.84e-05	0.0185	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Idarubicin—breast cancer	4.84e-05	0.0185	CbGdCrCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—breast cancer	4.66e-05	0.0178	CbGdCrCtD
Crizotinib—CSF1R—lymph node—breast cancer	4.52e-05	0.000542	CbGeAlD
Crizotinib—AURKA—Daunorubicin—Idarubicin—breast cancer	4.51e-05	0.0173	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Idarubicin—breast cancer	4.51e-05	0.0173	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Idarubicin—breast cancer	4.51e-05	0.0173	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—breast cancer	4.06e-05	0.0155	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—breast cancer	4.06e-05	0.0155	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—breast cancer	4.06e-05	0.0155	CbGdCrCtD
Crizotinib—Asthenia—Thiotepa—breast cancer	3.98e-05	0.000373	CcSEcCtD
Crizotinib—Diarrhoea—Vinorelbine—breast cancer	3.97e-05	0.000372	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—breast cancer	3.97e-05	0.000372	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Fluorouracil—breast cancer	3.96e-05	0.000371	CcSEcCtD
Crizotinib—Nausea—Melphalan—breast cancer	3.95e-05	0.00037	CcSEcCtD
Crizotinib—Malnutrition—Capecitabine—breast cancer	3.93e-05	0.000368	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—breast cancer	3.92e-05	0.000367	CcSEcCtD
Crizotinib—Oedema—Paclitaxel—breast cancer	3.9e-05	0.000366	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—breast cancer	3.9e-05	0.000365	CcSEcCtD
Crizotinib—CYP3A5—adipose tissue—breast cancer	3.89e-05	0.000466	CbGeAlD
Crizotinib—Infection—Paclitaxel—breast cancer	3.88e-05	0.000363	CcSEcCtD
Crizotinib—Nausea—Goserelin—breast cancer	3.85e-05	0.000361	CcSEcCtD
Crizotinib—Dysgeusia—Capecitabine—breast cancer	3.84e-05	0.00036	CcSEcCtD
Crizotinib—Shock—Paclitaxel—breast cancer	3.84e-05	0.00036	CcSEcCtD
Crizotinib—Dizziness—Vinorelbine—breast cancer	3.84e-05	0.00036	CcSEcCtD
Crizotinib—Nervous system disorder—Paclitaxel—breast cancer	3.83e-05	0.000359	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—breast cancer	3.82e-05	0.000358	CcSEcCtD
Crizotinib—Diarrhoea—Thiotepa—breast cancer	3.79e-05	0.000355	CcSEcCtD
Crizotinib—Skin disorder—Paclitaxel—breast cancer	3.79e-05	0.000355	CcSEcCtD
Crizotinib—Body temperature increased—Irinotecan—breast cancer	3.78e-05	0.000355	CcSEcCtD
Crizotinib—Body temperature increased—Mitoxantrone—breast cancer	3.78e-05	0.000355	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—breast cancer	3.78e-05	0.000354	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—breast cancer	3.76e-05	0.000352	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—breast cancer	3.76e-05	0.0144	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—breast cancer	3.76e-05	0.0144	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—breast cancer	3.76e-05	0.0144	CbGdCrCtD
Crizotinib—Anaemia—Docetaxel—breast cancer	3.75e-05	0.000351	CcSEcCtD
Crizotinib—Infestation—Methotrexate—breast cancer	3.74e-05	0.00035	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—breast cancer	3.74e-05	0.00035	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—breast cancer	3.71e-05	0.000347	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—breast cancer	3.71e-05	0.000347	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—breast cancer	3.7e-05	0.000347	CcSEcCtD
Crizotinib—Vomiting—Vinorelbine—breast cancer	3.69e-05	0.000346	CcSEcCtD
Crizotinib—Body temperature increased—Gemcitabine—breast cancer	3.69e-05	0.000345	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—breast cancer	3.67e-05	0.000344	CcSEcCtD
Crizotinib—Dizziness—Thiotepa—breast cancer	3.67e-05	0.000343	CcSEcCtD
Crizotinib—Rash—Vinorelbine—breast cancer	3.66e-05	0.000343	CcSEcCtD
Crizotinib—Dermatitis—Vinorelbine—breast cancer	3.66e-05	0.000343	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—breast cancer	3.65e-05	0.000342	CcSEcCtD
Crizotinib—Syncope—Docetaxel—breast cancer	3.64e-05	0.000341	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—breast cancer	3.63e-05	0.00034	CcSEcCtD
Crizotinib—Anaemia—Capecitabine—breast cancer	3.63e-05	0.00034	CcSEcCtD
Crizotinib—Body temperature increased—Fluorouracil—breast cancer	3.62e-05	0.00034	CcSEcCtD
Crizotinib—ABL1—lymph node—breast cancer	3.57e-05	0.000428	CbGeAlD
Crizotinib—Loss of consciousness—Docetaxel—breast cancer	3.56e-05	0.000334	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—breast cancer	3.55e-05	0.000333	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—breast cancer	3.54e-05	0.000331	CcSEcCtD
Crizotinib—Vomiting—Thiotepa—breast cancer	3.52e-05	0.00033	CcSEcCtD
Crizotinib—Syncope—Capecitabine—breast cancer	3.52e-05	0.00033	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—breast cancer	3.52e-05	0.00033	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—breast cancer	3.51e-05	0.000329	CcSEcCtD
Crizotinib—Paraesthesia—Paclitaxel—breast cancer	3.51e-05	0.000328	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—breast cancer	3.5e-05	0.000328	CcSEcCtD
Crizotinib—Infestation—Epirubicin—breast cancer	3.5e-05	0.000328	CcSEcCtD
Crizotinib—Rash—Thiotepa—breast cancer	3.5e-05	0.000327	CcSEcCtD
Crizotinib—Dermatitis—Thiotepa—breast cancer	3.49e-05	0.000327	CcSEcCtD
Crizotinib—Dyspnoea—Paclitaxel—breast cancer	3.48e-05	0.000326	CcSEcCtD
Crizotinib—Loss of consciousness—Capecitabine—breast cancer	3.45e-05	0.000323	CcSEcCtD
Crizotinib—Nausea—Vinorelbine—breast cancer	3.45e-05	0.000323	CcSEcCtD
Crizotinib—Dyspepsia—Paclitaxel—breast cancer	3.44e-05	0.000322	CcSEcCtD
Crizotinib—Asthenia—Mitoxantrone—breast cancer	3.44e-05	0.000322	CcSEcCtD
Crizotinib—Asthenia—Irinotecan—breast cancer	3.44e-05	0.000322	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—breast cancer	3.43e-05	0.000321	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	3.43e-05	0.000321	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Fluoxymesterone—breast cancer	3.42e-05	0.0131	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Fluoxymesterone—breast cancer	3.42e-05	0.0131	CbGdCrCtD
Crizotinib—Neutropenia—Doxorubicin—breast cancer	3.4e-05	0.000318	CcSEcCtD
Crizotinib—Decreased appetite—Paclitaxel—breast cancer	3.39e-05	0.000318	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—breast cancer	3.38e-05	0.000316	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Paclitaxel—breast cancer	3.37e-05	0.000316	CcSEcCtD
Crizotinib—Fatigue—Paclitaxel—breast cancer	3.37e-05	0.000315	CcSEcCtD
Crizotinib—Asthenia—Gemcitabine—breast cancer	3.35e-05	0.000313	CcSEcCtD
Crizotinib—Constipation—Paclitaxel—breast cancer	3.34e-05	0.000313	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	3.32e-05	0.000311	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—breast cancer	3.32e-05	0.000311	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—breast cancer	3.31e-05	0.00031	CcSEcCtD
Crizotinib—Oedema—Docetaxel—breast cancer	3.31e-05	0.00031	CcSEcCtD
Crizotinib—Nausea—Thiotepa—breast cancer	3.29e-05	0.000308	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—breast cancer	3.29e-05	0.000308	CcSEcCtD
Crizotinib—Infection—Docetaxel—breast cancer	3.29e-05	0.000308	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—breast cancer	3.29e-05	0.000308	CcSEcCtD
Crizotinib—Diarrhoea—Mitoxantrone—breast cancer	3.28e-05	0.000307	CcSEcCtD
Crizotinib—Diarrhoea—Irinotecan—breast cancer	3.28e-05	0.000307	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—breast cancer	3.26e-05	0.000305	CcSEcCtD
Crizotinib—Shock—Docetaxel—breast cancer	3.26e-05	0.000305	CcSEcCtD
Crizotinib—CYP3A5—female gonad—breast cancer	3.25e-05	0.00039	CbGeAlD
Crizotinib—Nervous system disorder—Docetaxel—breast cancer	3.25e-05	0.000304	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—breast cancer	3.24e-05	0.000303	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—breast cancer	3.24e-05	0.000303	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—breast cancer	3.24e-05	0.000303	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—breast cancer	3.21e-05	0.000301	CcSEcCtD
Crizotinib—Oedema—Capecitabine—breast cancer	3.2e-05	0.0003	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—breast cancer	3.2e-05	0.0003	CcSEcCtD
Crizotinib—Diarrhoea—Gemcitabine—breast cancer	3.19e-05	0.000299	CcSEcCtD
Crizotinib—Infection—Capecitabine—breast cancer	3.18e-05	0.000298	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—breast cancer	3.17e-05	0.000297	CcSEcCtD
Crizotinib—Dizziness—Irinotecan—breast cancer	3.17e-05	0.000297	CcSEcCtD
Crizotinib—Shock—Capecitabine—breast cancer	3.15e-05	0.000295	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—breast cancer	3.14e-05	0.000294	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—breast cancer	3.14e-05	0.000294	CcSEcCtD
Crizotinib—Diarrhoea—Fluorouracil—breast cancer	3.14e-05	0.000294	CcSEcCtD
Crizotinib—ABCB1—embryo—breast cancer	3.13e-05	0.000375	CbGeAlD
Crizotinib—Hypoaesthesia—Epirubicin—breast cancer	3.13e-05	0.000293	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—breast cancer	3.12e-05	0.000292	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—breast cancer	3.11e-05	0.000292	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—breast cancer	3.1e-05	0.000291	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—breast cancer	3.1e-05	0.00029	CcSEcCtD
Crizotinib—Body temperature increased—Paclitaxel—breast cancer	3.09e-05	0.000289	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—breast cancer	3.08e-05	0.000289	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—breast cancer	3.06e-05	0.000287	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—breast cancer	3.04e-05	0.000285	CcSEcCtD
Crizotinib—Vomiting—Irinotecan—breast cancer	3.04e-05	0.000285	CcSEcCtD
Crizotinib—Dizziness—Fluorouracil—breast cancer	3.03e-05	0.000284	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—breast cancer	3.03e-05	0.000284	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—breast cancer	3.03e-05	0.000283	CcSEcCtD
Crizotinib—CYP3A5—endocrine gland—breast cancer	3.02e-05	0.000363	CbGeAlD
Crizotinib—Rash—Mitoxantrone—breast cancer	3.02e-05	0.000283	CcSEcCtD
Crizotinib—Rash—Irinotecan—breast cancer	3.02e-05	0.000283	CcSEcCtD
Crizotinib—Dermatitis—Irinotecan—breast cancer	3.02e-05	0.000282	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—breast cancer	3.02e-05	0.000282	CcSEcCtD
Crizotinib—Paraesthesia—Docetaxel—breast cancer	2.97e-05	0.000278	CcSEcCtD
Crizotinib—Vomiting—Gemcitabine—breast cancer	2.97e-05	0.000278	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—breast cancer	2.96e-05	0.000277	CcSEcCtD
Crizotinib—Dyspnoea—Docetaxel—breast cancer	2.95e-05	0.000276	CcSEcCtD
Crizotinib—Rash—Gemcitabine—breast cancer	2.94e-05	0.000275	CcSEcCtD
Crizotinib—Dermatitis—Gemcitabine—breast cancer	2.94e-05	0.000275	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—breast cancer	2.94e-05	0.000275	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—breast cancer	2.92e-05	0.000274	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—breast cancer	2.92e-05	0.000273	CcSEcCtD
Crizotinib—Vomiting—Fluorouracil—breast cancer	2.92e-05	0.000273	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—breast cancer	2.91e-05	0.000273	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—breast cancer	2.89e-05	0.000271	CcSEcCtD
Crizotinib—Rash—Fluorouracil—breast cancer	2.89e-05	0.000271	CcSEcCtD
Crizotinib—Dermatitis—Fluorouracil—breast cancer	2.89e-05	0.000271	CcSEcCtD
Crizotinib—Paraesthesia—Capecitabine—breast cancer	2.88e-05	0.00027	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—breast cancer	2.88e-05	0.000269	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—breast cancer	2.87e-05	0.000269	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—breast cancer	2.86e-05	0.000268	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—breast cancer	2.86e-05	0.000268	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—breast cancer	2.86e-05	0.000268	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—breast cancer	2.86e-05	0.000268	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—breast cancer	2.85e-05	0.000267	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—breast cancer	2.85e-05	0.000267	CcSEcCtD
Crizotinib—Nausea—Irinotecan—breast cancer	2.84e-05	0.000266	CcSEcCtD
Crizotinib—Nausea—Mitoxantrone—breast cancer	2.84e-05	0.000266	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—breast cancer	2.83e-05	0.000265	CcSEcCtD
Crizotinib—Constipation—Docetaxel—breast cancer	2.83e-05	0.000265	CcSEcCtD
Crizotinib—Dyspepsia—Capecitabine—breast cancer	2.82e-05	0.000264	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—breast cancer	2.81e-05	0.000263	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—breast cancer	2.8e-05	0.000262	CcSEcCtD
Crizotinib—Asthenia—Paclitaxel—breast cancer	2.8e-05	0.000262	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—breast cancer	2.79e-05	0.000261	CcSEcCtD
Crizotinib—Nausea—Gemcitabine—breast cancer	2.77e-05	0.000259	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Capecitabine—breast cancer	2.77e-05	0.000259	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—breast cancer	2.76e-05	0.000259	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—breast cancer	2.75e-05	0.000258	CcSEcCtD
Crizotinib—Constipation—Capecitabine—breast cancer	2.74e-05	0.000257	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—breast cancer	2.74e-05	0.000256	CcSEcCtD
Crizotinib—Nausea—Fluorouracil—breast cancer	2.72e-05	0.000255	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—breast cancer	2.72e-05	0.000254	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—breast cancer	2.7e-05	0.000253	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—breast cancer	2.7e-05	0.000253	CcSEcCtD
Crizotinib—CYP3A4—female reproductive system—breast cancer	2.68e-05	0.000322	CbGeAlD
Crizotinib—Dysgeusia—Epirubicin—breast cancer	2.68e-05	0.000251	CcSEcCtD
Crizotinib—Diarrhoea—Paclitaxel—breast cancer	2.67e-05	0.00025	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—breast cancer	2.65e-05	0.0101	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—breast cancer	2.65e-05	0.0101	CbGdCrCtD
Crizotinib—Mediastinal disorder—Doxorubicin—breast cancer	2.62e-05	0.000245	CcSEcCtD
Crizotinib—Body temperature increased—Docetaxel—breast cancer	2.62e-05	0.000245	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—breast cancer	2.62e-05	0.000245	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—breast cancer	2.6e-05	0.000243	CcSEcCtD
Crizotinib—Dizziness—Paclitaxel—breast cancer	2.58e-05	0.000242	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—breast cancer	2.58e-05	0.000241	CcSEcCtD
Crizotinib—ABCB1—epithelium—breast cancer	2.55e-05	0.000306	CbGeAlD
Crizotinib—Body temperature increased—Capecitabine—breast cancer	2.53e-05	0.000237	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—breast cancer	2.53e-05	0.000237	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—breast cancer	2.53e-05	0.000237	CcSEcCtD
Crizotinib—Vomiting—Paclitaxel—breast cancer	2.48e-05	0.000233	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—breast cancer	2.48e-05	0.000232	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.47e-05	0.000231	CcSEcCtD
Crizotinib—Rash—Paclitaxel—breast cancer	2.46e-05	0.000231	CcSEcCtD
Crizotinib—Dermatitis—Paclitaxel—breast cancer	2.46e-05	0.00023	CcSEcCtD
Crizotinib—Syncope—Epirubicin—breast cancer	2.45e-05	0.00023	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—breast cancer	2.45e-05	0.000229	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—breast cancer	2.45e-05	0.00936	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—breast cancer	2.45e-05	0.00936	CbGdCrCtD
Crizotinib—Loss of consciousness—Epirubicin—breast cancer	2.4e-05	0.000225	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—breast cancer	2.39e-05	0.000223	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—breast cancer	2.37e-05	0.000222	CcSEcCtD
Crizotinib—Infection—Methotrexate—breast cancer	2.37e-05	0.000222	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—breast cancer	2.34e-05	0.000219	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—breast cancer	2.34e-05	0.000219	CcSEcCtD
Crizotinib—Nausea—Paclitaxel—breast cancer	2.32e-05	0.000217	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—breast cancer	2.32e-05	0.000217	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.31e-05	0.000217	CcSEcCtD
Crizotinib—Asthenia—Capecitabine—breast cancer	2.3e-05	0.000215	CcSEcCtD
Crizotinib—ABCB1—endometrium—breast cancer	2.29e-05	0.000275	CbGeAlD
Crizotinib—Syncope—Doxorubicin—breast cancer	2.27e-05	0.000213	CcSEcCtD
Crizotinib—CYP3A4—endocrine gland—breast cancer	2.27e-05	0.000272	CbGeAlD
Crizotinib—Leukopenia—Doxorubicin—breast cancer	2.27e-05	0.000212	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—breast cancer	2.26e-05	0.000212	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Gemcitabine—breast cancer	2.23e-05	0.00855	CbGdCrCtD
Crizotinib—Oedema—Epirubicin—breast cancer	2.23e-05	0.000209	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—breast cancer	2.22e-05	0.00851	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—breast cancer	2.22e-05	0.00851	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—breast cancer	2.22e-05	0.00851	CbGdCrCtD
Crizotinib—Loss of consciousness—Doxorubicin—breast cancer	2.22e-05	0.000208	CcSEcCtD
Crizotinib—Infection—Epirubicin—breast cancer	2.22e-05	0.000208	CcSEcCtD
Crizotinib—Shock—Epirubicin—breast cancer	2.2e-05	0.000206	CcSEcCtD
Crizotinib—Diarrhoea—Capecitabine—breast cancer	2.19e-05	0.000205	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—breast cancer	2.19e-05	0.000205	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—breast cancer	2.19e-05	0.000205	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—breast cancer	2.17e-05	0.000203	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—breast cancer	2.14e-05	0.000201	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.14e-05	0.0002	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—breast cancer	2.13e-05	0.000199	CcSEcCtD
Crizotinib—Dizziness—Capecitabine—breast cancer	2.12e-05	0.000198	CcSEcCtD
Crizotinib—ABCB1—uterus—breast cancer	2.11e-05	0.000253	CbGeAlD
Crizotinib—Vomiting—Docetaxel—breast cancer	2.1e-05	0.000197	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—breast cancer	2.1e-05	0.000197	CcSEcCtD
Crizotinib—Rash—Docetaxel—breast cancer	2.09e-05	0.000195	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—breast cancer	2.08e-05	0.000195	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—breast cancer	2.07e-05	0.000194	CcSEcCtD
Crizotinib—ABCB1—pituitary gland—breast cancer	2.07e-05	0.000249	CbGeAlD
Crizotinib—AURKA—Doxorubicin—Epirubicin—breast cancer	2.07e-05	0.00792	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—breast cancer	2.07e-05	0.00792	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—breast cancer	2.07e-05	0.00792	CbGdCrCtD
Crizotinib—Oedema—Doxorubicin—breast cancer	2.07e-05	0.000193	CcSEcCtD
Crizotinib—ABCB1—adipose tissue—breast cancer	2.06e-05	0.000248	CbGeAlD
Crizotinib—Gastrointestinal disorder—Methotrexate—breast cancer	2.06e-05	0.000193	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	2.06e-05	0.00787	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—breast cancer	2.06e-05	0.00787	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—breast cancer	2.06e-05	0.00787	CbGdCrCtD
Crizotinib—Fatigue—Methotrexate—breast cancer	2.06e-05	0.000193	CcSEcCtD
Crizotinib—Infection—Doxorubicin—breast cancer	2.05e-05	0.000192	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—breast cancer	2.04e-05	0.000191	CcSEcCtD
Crizotinib—Shock—Doxorubicin—breast cancer	2.03e-05	0.00019	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—breast cancer	2.03e-05	0.00019	CcSEcCtD
Crizotinib—Rash—Capecitabine—breast cancer	2.02e-05	0.000189	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—breast cancer	2.02e-05	0.000189	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—breast cancer	2.01e-05	0.000188	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—breast cancer	2e-05	0.000188	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—breast cancer	1.99e-05	0.000186	CcSEcCtD
Crizotinib—Nausea—Docetaxel—breast cancer	1.97e-05	0.000184	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—breast cancer	1.97e-05	0.000184	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—breast cancer	1.94e-05	0.000182	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—breast cancer	1.93e-05	0.000181	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—breast cancer	1.92e-05	0.00018	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—breast cancer	1.92e-05	0.00733	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—breast cancer	1.92e-05	0.00733	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—breast cancer	1.92e-05	0.00733	CbGdCrCtD
Crizotinib—Constipation—Epirubicin—breast cancer	1.91e-05	0.000179	CcSEcCtD
Crizotinib—Nausea—Capecitabine—breast cancer	1.9e-05	0.000178	CcSEcCtD
Crizotinib—ABCB1—female reproductive system—breast cancer	1.9e-05	0.000228	CbGeAlD
Crizotinib—Body temperature increased—Methotrexate—breast cancer	1.89e-05	0.000177	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—breast cancer	1.85e-05	0.000174	CcSEcCtD
Crizotinib—ABCB1—adrenal gland—breast cancer	1.85e-05	0.000222	CbGeAlD
Crizotinib—Dyspnoea—Doxorubicin—breast cancer	1.84e-05	0.000172	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—breast cancer	1.82e-05	0.00017	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—breast cancer	1.8e-05	0.000168	CcSEcCtD
Crizotinib—ABCB1—bone marrow—breast cancer	1.79e-05	0.000215	CbGeAlD
Crizotinib—Gastrointestinal disorder—Doxorubicin—breast cancer	1.78e-05	0.000167	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—breast cancer	1.78e-05	0.000167	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—breast cancer	1.77e-05	0.000165	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—breast cancer	1.76e-05	0.000165	CcSEcCtD
Crizotinib—ABCB1—female gonad—breast cancer	1.73e-05	0.000207	CbGeAlD
Crizotinib—Asthenia—Methotrexate—breast cancer	1.71e-05	0.00016	CcSEcCtD
Crizotinib—Body temperature increased—Doxorubicin—breast cancer	1.63e-05	0.000153	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—breast cancer	1.63e-05	0.000153	CcSEcCtD
Crizotinib—ABCB1—endocrine gland—breast cancer	1.61e-05	0.000193	CbGeAlD
Crizotinib—Asthenia—Epirubicin—breast cancer	1.6e-05	0.00015	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—breast cancer	1.58e-05	0.000148	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—breast cancer	1.53e-05	0.000143	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—breast cancer	1.52e-05	0.000142	CcSEcCtD
Crizotinib—Rash—Methotrexate—breast cancer	1.5e-05	0.000141	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—breast cancer	1.5e-05	0.000141	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—breast cancer	1.48e-05	0.000139	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—breast cancer	1.48e-05	0.000138	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—breast cancer	1.42e-05	0.000133	CcSEcCtD
Crizotinib—Nausea—Methotrexate—breast cancer	1.42e-05	0.000133	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—breast cancer	1.41e-05	0.000132	CcSEcCtD
Crizotinib—Rash—Epirubicin—breast cancer	1.41e-05	0.000132	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—breast cancer	1.41e-05	0.000132	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—breast cancer	1.37e-05	0.000128	CcSEcCtD
Crizotinib—Nausea—Epirubicin—breast cancer	1.33e-05	0.000124	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—breast cancer	1.31e-05	0.000123	CcSEcCtD
Crizotinib—Rash—Doxorubicin—breast cancer	1.3e-05	0.000122	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—breast cancer	1.3e-05	0.000122	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—breast cancer	1.23e-05	0.000115	CcSEcCtD
Crizotinib—ABCB1—lymph node—breast cancer	1.11e-05	0.000133	CbGeAlD
Crizotinib—CYP3A5—Metabolism—PIK3CG—breast cancer	2.01e-07	1.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—breast cancer	2.01e-07	1.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—breast cancer	2.01e-07	1.37e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—breast cancer	2.01e-07	1.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—breast cancer	2e-07	1.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—breast cancer	2e-07	1.36e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—breast cancer	2e-07	1.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—breast cancer	1.99e-07	1.36e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—breast cancer	1.99e-07	1.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACHE—breast cancer	1.97e-07	1.35e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—breast cancer	1.97e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—breast cancer	1.97e-07	1.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—breast cancer	1.97e-07	1.34e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—breast cancer	1.97e-07	1.34e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT2—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—breast cancer	1.96e-07	1.34e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—breast cancer	1.96e-07	1.33e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—breast cancer	1.95e-07	1.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—breast cancer	1.95e-07	1.33e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—breast cancer	1.95e-07	1.33e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—breast cancer	1.95e-07	1.33e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—breast cancer	1.94e-07	1.33e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—breast cancer	1.94e-07	1.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—breast cancer	1.94e-07	1.32e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—breast cancer	1.93e-07	1.32e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—breast cancer	1.92e-07	1.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—breast cancer	1.92e-07	1.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—breast cancer	1.91e-07	1.3e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—breast cancer	1.91e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—breast cancer	1.91e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—breast cancer	1.9e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—breast cancer	1.9e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—breast cancer	1.9e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—breast cancer	1.9e-07	1.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—breast cancer	1.9e-07	1.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—breast cancer	1.89e-07	1.29e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RELA—breast cancer	1.89e-07	1.29e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—breast cancer	1.89e-07	1.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—breast cancer	1.88e-07	1.28e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—breast cancer	1.88e-07	1.28e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—breast cancer	1.88e-07	1.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—breast cancer	1.88e-07	1.28e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—breast cancer	1.88e-07	1.28e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—breast cancer	1.87e-07	1.28e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP17A1—breast cancer	1.87e-07	1.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—breast cancer	1.86e-07	1.27e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—breast cancer	1.86e-07	1.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS1—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—breast cancer	1.85e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—breast cancer	1.84e-07	1.26e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—breast cancer	1.84e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—breast cancer	1.84e-07	1.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—breast cancer	1.83e-07	1.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—breast cancer	1.83e-07	1.25e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2D6—breast cancer	1.81e-07	1.24e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—breast cancer	1.81e-07	1.24e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—breast cancer	1.81e-07	1.24e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—breast cancer	1.81e-07	1.24e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—breast cancer	1.8e-07	1.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—breast cancer	1.79e-07	1.22e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—breast cancer	1.79e-07	1.22e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—breast cancer	1.79e-07	1.22e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—breast cancer	1.78e-07	1.22e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—breast cancer	1.78e-07	1.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—breast cancer	1.78e-07	1.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOA2—breast cancer	1.78e-07	1.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—breast cancer	1.78e-07	1.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—breast cancer	1.77e-07	1.21e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—breast cancer	1.77e-07	1.2e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—breast cancer	1.77e-07	1.2e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—breast cancer	1.76e-07	1.2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	1.75e-07	1.2e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—breast cancer	1.75e-07	1.19e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—breast cancer	1.75e-07	1.19e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—breast cancer	1.74e-07	1.19e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—breast cancer	1.74e-07	1.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—breast cancer	1.74e-07	1.19e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—breast cancer	1.74e-07	1.18e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—breast cancer	1.73e-07	1.18e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—breast cancer	1.73e-07	1.18e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FASN—breast cancer	1.73e-07	1.18e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—breast cancer	1.72e-07	1.17e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—breast cancer	1.71e-07	1.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—breast cancer	1.71e-07	1.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—breast cancer	1.71e-07	1.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—breast cancer	1.7e-07	1.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—breast cancer	1.7e-07	1.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.7e-07	1.16e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—breast cancer	1.7e-07	1.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—breast cancer	1.7e-07	1.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—breast cancer	1.69e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—breast cancer	1.68e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—breast cancer	1.68e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—breast cancer	1.68e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—breast cancer	1.68e-07	1.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RELA—breast cancer	1.67e-07	1.14e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—breast cancer	1.67e-07	1.14e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—breast cancer	1.67e-07	1.14e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—breast cancer	1.66e-07	1.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—breast cancer	1.66e-07	1.13e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—breast cancer	1.66e-07	1.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—breast cancer	1.66e-07	1.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—breast cancer	1.66e-07	1.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—breast cancer	1.65e-07	1.13e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—breast cancer	1.65e-07	1.12e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—breast cancer	1.65e-07	1.12e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—breast cancer	1.64e-07	1.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—breast cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—breast cancer	1.63e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—breast cancer	1.62e-07	1.11e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—breast cancer	1.62e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—breast cancer	1.62e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—breast cancer	1.62e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—breast cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—breast cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—breast cancer	1.61e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—breast cancer	1.6e-07	1.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—breast cancer	1.59e-07	1.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—breast cancer	1.58e-07	1.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—breast cancer	1.58e-07	1.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1B1—breast cancer	1.57e-07	1.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—breast cancer	1.57e-07	1.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—breast cancer	1.56e-07	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—breast cancer	1.56e-07	1.06e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—breast cancer	1.55e-07	1.06e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—breast cancer	1.55e-07	1.06e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—breast cancer	1.55e-07	1.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.54e-07	1.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—breast cancer	1.54e-07	1.05e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—breast cancer	1.54e-07	1.05e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—breast cancer	1.53e-07	1.05e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—breast cancer	1.53e-07	1.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—breast cancer	1.52e-07	1.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—breast cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—breast cancer	1.52e-07	1.03e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—breast cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—breast cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—breast cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—breast cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—breast cancer	1.51e-07	1.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—breast cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOA1—breast cancer	1.5e-07	1.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—breast cancer	1.49e-07	1.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—breast cancer	1.49e-07	1.01e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—breast cancer	1.49e-07	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STK11—breast cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—breast cancer	1.48e-07	1.01e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—breast cancer	1.47e-07	1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—breast cancer	1.47e-07	1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—breast cancer	1.46e-07	9.93e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—breast cancer	1.45e-07	9.87e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—breast cancer	1.43e-07	9.78e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—breast cancer	1.43e-07	9.78e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—breast cancer	1.43e-07	9.77e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—breast cancer	1.43e-07	9.75e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—breast cancer	1.43e-07	9.75e-07	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—breast cancer	1.43e-07	9.74e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—breast cancer	1.43e-07	9.73e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—breast cancer	1.42e-07	9.7e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—breast cancer	1.42e-07	9.68e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—breast cancer	1.4e-07	9.58e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—breast cancer	1.39e-07	9.49e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—breast cancer	1.39e-07	9.47e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—breast cancer	1.38e-07	9.41e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—breast cancer	1.38e-07	9.38e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—breast cancer	1.37e-07	9.35e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—breast cancer	1.37e-07	9.34e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—breast cancer	1.37e-07	9.34e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—breast cancer	1.35e-07	9.21e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ITPR1—breast cancer	1.35e-07	9.19e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—breast cancer	1.33e-07	9.1e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—breast cancer	1.33e-07	9.09e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—breast cancer	1.33e-07	9.08e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—breast cancer	1.33e-07	9.07e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—breast cancer	1.33e-07	9.06e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—breast cancer	1.32e-07	9.02e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—breast cancer	1.32e-07	9e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—breast cancer	1.32e-07	8.97e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—breast cancer	1.3e-07	8.88e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—breast cancer	1.3e-07	8.84e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—breast cancer	1.29e-07	8.8e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—breast cancer	1.28e-07	8.74e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—breast cancer	1.28e-07	8.7e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—breast cancer	1.27e-07	8.68e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—breast cancer	1.27e-07	8.65e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—breast cancer	1.27e-07	8.63e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—breast cancer	1.26e-07	8.63e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—breast cancer	1.26e-07	8.58e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOR1—breast cancer	1.26e-07	8.58e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—breast cancer	1.26e-07	8.58e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.26e-07	8.58e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—breast cancer	1.25e-07	8.52e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—breast cancer	1.23e-07	8.39e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—breast cancer	1.22e-07	8.33e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—breast cancer	1.21e-07	8.27e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—breast cancer	1.2e-07	8.22e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—breast cancer	1.19e-07	8.15e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—breast cancer	1.19e-07	8.13e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—breast cancer	1.18e-07	8.07e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—breast cancer	1.18e-07	8.04e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—breast cancer	1.18e-07	8.02e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—breast cancer	1.17e-07	7.96e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—breast cancer	1.16e-07	7.92e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—breast cancer	1.15e-07	7.87e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—breast cancer	1.15e-07	7.85e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—breast cancer	1.14e-07	7.8e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—breast cancer	1.13e-07	7.71e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—breast cancer	1.13e-07	7.69e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—breast cancer	1.11e-07	7.58e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—breast cancer	1.09e-07	7.46e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—breast cancer	1.09e-07	7.43e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—breast cancer	1.05e-07	7.19e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—breast cancer	1.05e-07	7.13e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—breast cancer	1.03e-07	6.99e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—breast cancer	1e-07	6.85e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—breast cancer	1e-07	6.83e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—breast cancer	1e-07	6.83e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—breast cancer	9.68e-08	6.6e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—breast cancer	9.38e-08	6.4e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—breast cancer	9.34e-08	6.37e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—breast cancer	9.26e-08	6.32e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—breast cancer	9.23e-08	6.3e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—breast cancer	8.86e-08	6.04e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—breast cancer	8.21e-08	5.6e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—breast cancer	8.17e-08	5.58e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—breast cancer	8.1e-08	5.53e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—breast cancer	7.75e-08	5.29e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—breast cancer	7.67e-08	5.23e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—breast cancer	7.16e-08	4.88e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—breast cancer	7.09e-08	4.84e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—breast cancer	7.08e-08	4.83e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—breast cancer	6.18e-08	4.22e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—breast cancer	5.78e-08	3.95e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—breast cancer	4.36e-08	2.98e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—breast cancer	3.56e-08	2.43e-07	CbGpPWpGaD
